Published in Eur J Clin Pharmacol on September 20, 2016
Alterations in pancreatic β cell function and Trypanosoma cruzi infection: evidence from human and animal studies. Parasitol Res (2016) 0.75
Clincal interpretation of the anti-tuberculosis drug concentrations in diabetic and non-diabetic tuberculosis patients. Eur J Clin Pharmacol (2017) 0.75
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med (2001) 14.48
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med (2002) 4.19
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis (2007) 3.15
Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest (2001) 3.10
Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med (2009) 2.72
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis (2006) 2.47
Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg (2009) 2.30
Will China's nutrition transition overwhelm its health care system and slow economic growth? Health Aff (Millwood) (2008) 2.15
Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis (2006) 2.10
Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect (2008) 1.97
Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc (2011) 1.53
Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis (2010) 1.48
Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis (2008) 1.40
Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Indian J Med Res (2007) 1.36
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother (2009) 1.36
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs (2014) 1.34
Tuberculosis complicated by diabetes mellitus at shanghai pulmonary hospital, china. Jpn J Infect Dis (2009) 1.20
Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis--a report from South India. J Diabetes Complications (2013) 0.96
Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother (2012) 0.92
Evaluation of an intermittent six-month regimen in new pulmonary tuberculosis patients with diabetes mellitus. Indian J Tuberc (2007) 0.92
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother (2013) 0.91
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J Tuberc Lung Dis (2016) 0.77
Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb) (2014) 0.75
Effects of glucose and ascorbic acid on absorption and first pass metabolism of isoniazid in rats. Chem Pharm Bull (Tokyo) (1991) 0.75